HCA

HCA is the scale leader in U.S. hospital-based care, with dense market positions that support referral capture, payer leverage, and operational standardization across acute care and ambulatory settings. Recent results reinforce pricing/acuity resilience: 1Q26 same-facility equivalent admissions rose 1.3% and revenue per equivalent admission rose 3.1%, even as respiratory volumes and a January storm pressured typical seasonal demand. The key industry swing factor remains labor and reimbursement (including Medicaid supplemental programs), which can move margins quickly.

Financially, 1Q26 revenue grew 4.3% to $19.109B and adjusted EBITDA grew 1.9% to $3.802B, while operating cash flow rose 22.0% to $2.014B; 2025 revenue was $75.600B with net income of $6.784B. Leverage is meaningful: as of March 31, 2026 HCA reported total debt of $48.023B versus cash of $0.94B, and stockholders’ equity is negative, reflecting heavy buybacks and a debt-forward capital structure. Valuation is hard to pin down from the provided data (P/E not supplied), but 2026 guidance implies continued earnings power with revenue $76.5B–$80.0B and EPS $29.10–$31.50.

Over the next 12 months, the bull case is steady same-facility growth plus incremental reimbursement tailwinds, with management’s 2026 guidance providing an anchor for expectations. Key catalysts are normalization of seasonal volumes, sustained pricing/acuity, and any upward revision to guidance if supplemental payments persist. Key risks are payer-mix pressure (especially exchange dynamics), higher interest expense sensitivity given large debt, and weather/episodic volume disruptions.

Recommendation: HOLD. HCA offers durable cash generation and guidance-backed earnings visibility, but the balance-sheet leverage and policy/payer uncertainty reduce the margin of safety at today’s scale-driven valuation.